WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:

C07K 14/705, 16/18, 16/42, G01N 33/564,

C12N 15/12, C12P 21/02, A61K 38/17

(11) International Publication Number:

WO 99/11667

C12N 15/12, C12P 21/02, A61K 38/17

(43) International Publication Date:

11 March 1999 (11.03.99)

(21) International Application Number:

PCT/EP98/05518

(22) International Filing Date:

31 August 1998 (31.08.98)

(30) Priority Data:

97870127.4

29 August 1997 (29.08.97)

EP

(71) Applicant (for all designated States except US): INNOGENET-ICS N.V. [BE/BE]; Industriepark Zwijnaarde 7, P.O. Box 4, B-9052 Ghent (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MEHEUS, Lydie [BE/BE]; Gontrodeheirweg 120, B-9820 Merelbeke (BE). LÜHRMANN, Reinhard, Georg [DE/DE]; Philipps-Universität Marburg, Institut für Molekularbiologie und Tumorforschug, Emil-Mannkopff-Strasse 2, D-35037 Marburg (DE). UNION, Ann [BE/BE]; Savooien 15, B-9880 Aalter (BE). RAYMACKERS, Joseph [BE/BE]; Zuiderbiesten 10, B-9810 Eke (BE).

(74) Agent: DE CLERCQ, Ann; Innogenetics N.V., Industriepark Zwijnaarde 7, P.O. Box 4, B-9052 Ghent (BE). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHYLATED, SmD HOMOLOGOUS PEPTIDES, REACTIVE WITH THE ANTIBODIES FROM SERA OF LIVING BEINGS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS

(57) Abstract

The present invention relates to a method of producing certain peptides containing methylated arginines that are followed by a glycine residue and that constitute immunogenic determinants of antibodies present in sera from patients with systemic lupus erythematosus, or Epstein-Barr virus and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptides for diagnosis and treatment of systemic lupus erythematosus and related diseases, and diseases in which Epstein-Barr virus has been implicated.

The state of the s